3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Investor Presentation (May 2017)
20 slides from 3b Blackbio Dx's investor presentation, May 29, 2017
Slide 1: Kilpest India Limited cover letter to BSE
KILPEST INDIA LIMITED <= S C REGD. OFFICE & FACTORY : SUREWN QUALITY CERTIFICATION | 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 (INDIA) Lise soon ssees| Tel : (91-755) 2586536, 2586537, 2586439 FAXNO. : (91-755) 2580438 Email : kilpest@bsnl.in visit us at : www.kilpest.com kilpestbpl@yahoo.c
Slide 2: Investor Presentation May 2017
Farmers trusted Agro-input partner for 44 years Reliable & affordable healthcare diagnostics solutions INVESTOR PRESENTATION May 2017
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to
Slide 4: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides - 70 • Bio pesticide - 07 • Antibacterials - 01 • Bio fungicide - 01 • Fungicides - 15 • Bio fertilizers - 05 • Herbicides - 11 • Bio nematicides - 01 • Public Health - 11 • Public Health - 02 • Microferti
Slide 5: Business Overview and Strengths
Business Overview and Strengths Experienced team & state of art facility located in center of India- with GST implementation this should give a boost to the company • 44yrs old Pesticide Formulation Company, well established in central India, strong brand equity in central India especially in Madhya
Slide 6: Financial Performance: Key Highlights
Financial Performance : Key Highlights FY16, KILPEST (Consolidated) FY17 FY16 1732.72 FY17, 113.18 238.05% Net sales 1616.33 1732.72 FY17, Profit before tax 139.69 43.69 1616.33 FY16, 33.48 Profit after tax 113.18 33.48 Paid up Equity share capital 640.81 640.81 Revenue PAT Reserves 482.87 393.46 (C
Slide 7: 2016 Agri-market Conditions
2016 Agri-market Conditions
Slide 8: Company Overview
Company Overview Although the financials for agrochemical alone have been affected due to reasons mentioned in above newspaper clippings (due to lower pest infestation) this year. However, the company hopes to do better in coming year with its thrust on plant growth products (which are not affected
Slide 9: Financial Highlights- 3B BlackBio Biotech (FY17)
Financial Highlights- 3B BlackBio Biotech (FY17) FY17, FY17, 315.68 93.95% 150.57 204.80% FY16, 162.76 FY16, 49.4 Revenue EBITDA FY17, FY17, 112.56 90.19 509.75% 509.39% FY16, FY16, 18.46 14.8 Rs. In Lakhs PBT PAT BCR ABL I JAK 2 I PML RARA I KRAS I HLA B27 I MDR TB I H1N1 Dengue I Chikungunya I HPV
Slide 10: Margin Profile- 3B BlackBio Biotech (FY17)
Margin Profile- 3B BlackBio Biotech (FY17) FY17, 72.50% FY16, FY17, 57.81% 47.70% FY16, 30.35% Value Addition* EBITDA Margin FY17, FY17, 28.57% 42.93% FY16, 20.46% FY16, 9.09% Rs. In Lakhs EBIT Margin PAT Margin *Revenue (-) cost of raw materials consumed (-) change in inventories BCR ABL I JAK 2 I
Slide 11: Financial Highlights- 3B BlackBio Biotech (Q4 FY17)
Financial Highlights- 3B BlackBio Biotech (Q4 FY17) Q4 FY17, Q4 FY17, 93.62 119.05% 40.86% 33.57 Q4 FY16, 23.83 Q4 FY16, 42.74 Revenue EBITDA Q4 FY17, Q4 FY17, 20.55 15.65 154.17% 79.16% Q4 FY16, Q4 FY16, 8.74 8.09 PBT PAT Rs. In Lakhs BCR ABL I JAK 2 I PML RARA I KRAS I HLA B27 I MDR TB I H1N1 Deng
Slide 12: Industry Potential- Molecular Diagnostics
Industry Potential- Molecular Diagnostics • The global IVD Market US$ 54.7 billion in the year 2015 (CAGR of 5-6%)1 Highest Growth Rate • Molecular Diagnostic Market US$ 7 billion (CAGR of 10-15%)2 • Indian diagnostics industry was around Rs. 377 billion in 2014-2015 and will continue to grow by a C
Slide 13: Demand drivers for the Indian Diagnostic Industry
Demand drivers for the Indian Diagnostic Industry • Increased focus on advanced diagnostics • changing costs and quality of healthcare, • rising medical tourism, • evolution of disease profiles, • technology as a driving force, • increase in evidence-based treatments / Drug response monitoring • cha
Slide 14: Molecular Diagnostics
Molecular Diagnostics • The process of identifying a disease by studying molecules, such as proteins, DNA, and RNA, in a tissue or fluid. • Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome—the individual’s genetic code and how their cells express the
Slide 15: Winning Strategy
Winning Strategy • Proprietary kits designed, developed & validated in-house • Well accepted assays across wide customer base PAN India • Continuous R&D initiatives for International quality product • Wide range of Diagnostic kits- Infectious, Oncology & Genetics • Import substitution with price adv
Slide 16: New assays introduced recently
New assays introduced recently Infectious Disease TRUPCR® CMV Kit Detection of Cytomegalovirus on real-time PCR TRUPCR® HSV 1/2 Kit Detection and differentiation of Herpes Simplex virus 1 & 2 on real-time PCR Tropical Diseases TRUPCR® Dengue / Chikungunya RT PCR Kit Simultaneous detection of Dengue
Slide 17: New Customers added in Q4 2016-17
New Customers added in Q4 2016-17 • Leading Cancer Hospital in Gujrat • 2 Diagnostic Labs in Ahmedabad • Leading Charitable Hospital in Mumbai • Leading Multispecialty Hospital in Mumbai • Branch of Leading National Diagnostic Network in Pune • 3 Renowned Diagnostic Labs in Chennai • 2 Diagnostic La
Slide 18: Products in Pipeline
Products in Pipeline • Coagulation Prognostic Panel • Factor V Mutation Detection- specific gene mutation that results in an increased tendency to form abnormal blood clots that can block blood vessels hence diagnosis required by clinician/ surgeons. • Factor II Mutation Detection- human gene mutati
Slide 19: PCR based Molecular Diagnostic Kit Range
PCR based Molecular Diagnostic Kit Range Genetics & Oncology TRUPCR® BCR-ABL Qualitative Kit – M m µ Detection and differentiation of BCR-ABL major (M), minor (m) and micro (µ) transcripts TRUPCR® BCR-ABL Quantitative Kit – M m µ Detection, differentiation and quantitation of BCR-ABL major (M), mino
Slide 20: For further information, please contact
For further information, please contact: KILPEST INDIA LIMITED 3B BLACKBIO BIOTECH INDIA LIMITED 7-C Industrial Area , Govindpura, Bhopal- 462023[M.P.] INDIA 7-C Industrial Area , Govindpura, Bhopal- 462023 [M.P.] INDIA Phone :: +91-755-2586536 Phone :: +91-755-4077847 Fax :: +91-755-2580438 Fax ::